RLAY · Relay Therapeutics, Inc. · Executive Compensation
$16.12
+0.21 (+1.32%)
At close · Nov 20
Return incl. dividend (before tax)
Market Cap
$3.56B
Shares
220.96M
Volume · Nov 20
3.98M
Avg daily vol (3M)
2.93M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $4,646,454 |
| Thomas Catinazzo | Chief Financial Officer | $1,568,613 |
| Brian R. Adams | Former Chief Legal Officer | $1,177,329 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $13,079,301 |
| Donald Bergstrom | M.D., Ph.D. President, Research & Development | $6,613,397 |
| Peter Rahmer | Chief Corporate Development Officer | $4,963,636 |
| Thomas Catinazzo | Chief Financial Officer | $4,400,994 |
| Brian R. Adams | Chief Legal Officer | $4,365,263 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $19,770,838 |
| Donald Bergstrom | M.D., Ph.D. President, Research & Development | $8,573,063 |
| Peter Rahmer | Chief Corporate Development Officer | $6,782,446 |
| Thomas Catinazzo | Chief Financial Officer | $5,219,149 |
| Brian R. Adams | Chief Legal Officer | $4,510,775 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $8,121,840 |
| Donald Bergstrom | M.D., Ph.D. President, Research & Development | $3,783,338 |
| Thomas Catinazzo | Chief Financial Officer | $2,457,265 |
| Brian R. Adams | Chief Legal Officer | $2,455,974 |
| Peter Rahmer | Chief Corporate Development Officer | $2,427,957 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $8,532,948 |
| Donald Bergstrom | M.D., Ph.D. President, Research & Development | $3,539,792 |
| Brian R. Adams | Chief Legal Officer | $1,889,635 |
| Thomas Catinazzo | Chief Financial Officer | $1,836,279 |
| Andy Porter | Chief Administrative Officer | $1,754,609 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $3,576,319 |
| Donald Bergstrom | M.D., Ph.D. President, Research & Development | $1,105,092 |
| Brian R. Adams | Chief Legal Officer | $800,201 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Sanjiv K. Patel | President and Chief Executive Officer | $3,529,596 |
| Donald Bergstrom | President, Research & Development | $916,516 |
| Brian R. Adams | Chief Legal Officer | $619,497 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Habib Dable | member of the Board | Appointed | 2025-11-06 |
| Lonnel Coats | member of the Board | Appointed | 2025-11-06 |
|
Jami Ruben
“Ms. Rubin’s resignation is not the result of any dispute or disagreement with the Company.”
|
Class III Director | Resigned | 2025-06-11 |
| Sekar Kathiresan, M.D. | class III director | Appointed | 2022-07-27 |
|
Dipchand (Deep) Nishar
“Mr. Nishar’s resignation was not the result of any dispute or disagreement with the Company, the Company’s management or the Board on any matter relating to the Company’s operations, policies or practices.”
|
Class III director | Resigned | 2021-12-09 |
Leadership
- Thomas Catinazzo CFO
- Brian R. Adams General Counsel
- Claire Mazumdar Board Member
- Douglas S. Ingram Board Member
- Habib Dable Board Member
- Lonnel Coats Board Member
- Sekar Kathiresan, M.D. Board Member
Key facts
CIK
1812364
CUSIP
75943R102
13F (30d)
276 filings
247 filers
Visit website
Investor relations